Head and neck cancer: which chemo combo works best?
NCT ID NCT01154920
First seen Nov 10, 2025 · Last updated Jun 21, 2026 · Updated 30 times
Summary
This study compares two chemotherapy combinations for people with advanced head and neck cancer that hasn't been treated yet. One group gets paclitaxel, carboplatin, and cetuximab weekly; the other gets cetuximab, docetaxel, cisplatin, and fluorouracil in cycles. The goal is to see which combination helps patients live longer without the cancer growing, and to compare side effects. About 128 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 20115, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy drugs (paclitaxel, carboplatin, cetuximab, docetaxel, cisplatin, fluorouracil)
What this could lead to
If successful, this trial could identify a more effective chemotherapy regimen for advanced head and neck cancer, potentially improving survival and quality of life.
What could go wrong
This is a phase 2 trial with only 128 participants, so results may not apply to all patients. Chemotherapy side effects can be severe, and the better regimen may still have limited long-term benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.